The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Blood myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) are correlated with neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS).
 
Iris Yeong- Fung Sheng
No Relationships to Disclose
 
C. Marcela Diaz-Montero
No Relationships to Disclose
 
Patricia A. Rayman
No Relationships to Disclose
 
Wei (Auston) Wei
No Relationships to Disclose
 
Jaleh Fallah
No Relationships to Disclose
 
James Finke
No Relationships to Disclose
 
Jin Sub Kim
No Relationships to Disclose
 
Paul G. Pavicic
No Relationships to Disclose
 
Marcelo Lamenza
No Relationships to Disclose
 
Donna Company
No Relationships to Disclose
 
Andrew J. Stephenson
Speakers' Bureau - Genomic Health
 
Steven Campbell
No Relationships to Disclose
 
Georges-Pascal Haber
No Relationships to Disclose
 
Byron H Lee
No Relationships to Disclose
 
Omar Y. Mian
No Relationships to Disclose
 
Timothy D. Gilligan
Travel, Accommodations, Expenses - WellPoint
 
Brian I. Rini
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche/Genentech; synthorx
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Merck; Pfizer
 
Jorge A. Garcia
Consulting or Advisory Role - Bayer; Eisai; Exelixis; Genentech/Roche; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Genentech/Roche; Medivation/Astellas; Merck; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Lilly (Inst); Orion (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Exelixis; Genentech/Roche; Medivation/Astellas; Merck; Pfizer; Sanofi
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Biocept; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genentech; Merck; Pfizer; QED Therapeutics; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Genentech
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncogenex (Inst); Pfizer (Inst)
 
Moshe Chaim Ornstein
Consulting or Advisory Role - Eisai; Exelixis; Pfizer
Speakers' Bureau - Exelixis
Travel, Accommodations, Expenses - Exelixis